Trending...
- Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
- Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is
- CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
RALEIGH, N.C., April 16, 2021 /PRNewswire/ -- Contego Medical, Inc., a leading developer of innovative cardiovascular devices, today announced receipt of CE Mark approval for the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System).
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
- Calvetta Phair Founder & CEO Earns AOPA Foundation Flight Training Scholarship, Inspiring a New Generation of STEM Dreamers in Underserved Communities
- 40 Years Strong: IMI Association Executives Expands Impact in a Changing Nonprofit Landscape
- MTV EMA Nominee and WOA Founder Oliver Sean Conferred Doctor of Musical Arts (DMA) Degree
- Karen D. Gentry Announces New Book Focused on Relationships and Personal Growth
- New from Regal House Publishing, The Meaning of Fear, a psychological crime drama
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
- New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
- CCHR Report Links 145 Violent Incidents to Psychiatric Drug Exposure, Urges National Oversight and Action
- Food Journal Magazine Unveils Its Latest 'Best of Los Angeles' Culinary Discoveries
- Boston Industrial Solutions Launches Natron® 717S Series: A New Flexible UV LED Ink for Ricoh GH2220 Printheads
- ZionSphere Launches Volunteer Program Opens Remote & Local Opportunities for Faith-Minded America
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
0 Comments
Latest on ncarol.com
- Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
- New from Regal House Publishing, Local Heroes, Lyric poems exploring themes drawn from ordinary life
- New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
- Melospeech Inc. Awarded New NYSDOH BEI Contract in New York
- Five-star Review for Berklee School of Music Textbook
- ZionSphere Launches Multi-Platform Virtual Reality Faith Experience Built from Rocky Mount, NC
- Rocky Mount Founder Builds Virtual Reality Bible Experiences After Receiving Divine Directive
- Advanced TeleSensors Appoints AgeTech Innovator Tiffany Wey, MBA as Vice President of Sales & Marketing
- Daniel Kaufman Real Estate Venture LoneStar Kaufman Development Partners Expands
- Brian D Chase Selected to the 2026 Nation's Top One Percent Personal Injury Lawyers
- Most Americans Choose Their Water Brand Because of Its Natural Source — Yet Fewer Than 3 in 10 Understand What Spring Water Actually Is
- Unlocking Multi-Sector Growth; Graphite Acquisition Powers EV Entry While Streamlined Consumer Snack Business Fuels Growth: (N A S D A Q: SOWG)
- Permian Museum Adds Carbonaceous Chondrite Reference Photos
- L2 Aviation Receives FAA STC and PMA for Klatt Works SAVED™ Smoke Vision System
- Axencis Launches Performance Partnership for Brand Protection
- CCHR Says New OIG Report Raises Concerns about Drugging Elderly with Antipsychotics
- Project Pretzel Introduces a New System for Running Renovation Projects with Built In Contracts and Real Time Execution
- Plated Possibilities Launches Luxury Culinary Series Celebrating Black Women Chefs In Charlotte
- Generous Anonymous Gift Brings New Life to Piedmont Crossing Dog Park
- Freedomtech Solutions creates 'Global Data Centre Network (IDCN)'